EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

Invasive Breast Cancer Clinical Trial

Official title:

EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast and Their Association With the Clinicopathological Prognostic Paremeters

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05703815
• Other study ID #: Soh-Med-23-01-34
• Status: Not yet recruiting
• Start date: January 2023
• Est. completion date: March 2023

Study information

• Verified date: January 2023
• Source: Sohag University
• Contact: Rasha M Abdelkareem, lecturer
• Phone: 01158408563
• Email: rasha_abdelkareem[@]med.sohag.edu.eg
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world.

In Egypt, breast cancer represents the 2nd most diagnosed cancer among all population. But among Egyptian females it represents the 1st diagnosed cancer representing 32.4%.

The main cause of death in breast cancer patients is tumor metastasis. Although only 5-10% of recently diagnosed breast cancer cases show metastasis to distant sites, but still there is a high risk for metastasis in patients with localized primary tumor following successful surgical management.

Epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule. It modifies cadherin mediated cell adhesion and it induces epithelial cell migration and proliferation. Some authors elucidate that EpCAM is involved in metastasis.

P53 is a known tumor suppressor gene involved in the control of cell cycle, DNA repair and apoptosis. It's one of the most mutated genes in cancer including breast cancer. Mutant p53 has a big role in tumor progression.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: March 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Both incisional and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study.

3. Complete clinical data.

Exclusion Criteria:

1. Patients with recurrence of the primary tumor.

2. Patients with a history of preoperative chemotherapy and/or radiotherapy.

3. Insufficient or tiny tissue biopsies

Related Conditions & MeSH terms

• Breast Neoplasms
• Carcinoma, Ductal
• Invasive Breast Cancer

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnosis of breast cancer	Immunohistochemical expression of EpCAM and P53 in IDC of the breast	two day after staining sections with Immnnohistochemical markers